Prev Close | 268.35 |
Open | 265.51 |
Day Low/High | 263.78 / 268.00 |
52 Wk Low/High | 176.36 / 292.75 |
Volume | 546.48K |
Prev Close | 268.35 |
Open | 265.51 |
Day Low/High | 263.78 / 268.00 |
52 Wk Low/High | 176.36 / 292.75 |
Volume | 546.48K |
Exchange | NASDAQ |
Shares Outstanding | 255.76B |
Market Cap | 66.14B |
P/E Ratio | 23.27 |
Div & Yield | N.A. (N.A) |
Of stocks seeing the biggest gains since the presidential election, only a few owe their success to Trump.
Trade from the long side, but have a sell stop below $149 in case of a reversal.
Let's examine VRTX's sharp decline today.
Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday
The Nasdaq and S&P 500 ended at records for the second day in a row.
It's a wonder to me how split this market really is.
"The rally in the face of today's data (detailed by Peter Boockvar in the previous post) tells me how much machines and algos dominate trading: a mild winter goosed construction jobs service job data is so-so ISM services has just given back the ent...
It's pretty normal to have profit-taking after such a strong first quarter.
A rally in crude oil gave rise to the energy sector in a mixed day of trading.
Base building pays off.
Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.
Jana Partners are placing three members on Tiffany's board.
Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.
Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday.
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
Even among the losers, buys are scarce.
Buy signals have not lasted more than two months, so far.
What stocks have changed direction in the past week.
These stocks are down some 20% over the last 30 months and look ripe for a rise.
It might be best to make this a late-afternoon purchase.
The answer is that new data came out.
The rate of decline slowed into the base, just what chartists like to see.
There are some good buying ideas among these stocks.